v3.24.3
Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Mar. 31, 2020
Jun. 30, 2019
Sep. 30, 2018
Dec. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Jun. 30, 2015
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue $ 30,017,000 $ 3,318,000                           $ 48,167,000 $ 8,152,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab)                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue   $ 0                           0 $ 0
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                             $ 1,000,000.0    
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | IND clearance from the FDA                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                         $ 4,000,000.0        
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Phase 2 clinical trial initiation                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                     $ 3,000,000.0            
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                 $ 5,000,000.0                
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue               $ 5,000,000.0                  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue             $ 10,000,000.0                    
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue             $ 5,000,000.0                    
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue           $ 10,000,000.0                      
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First BLA approval - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue         $ 20,000,000.0                        
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First MAA approval - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue         $ 10,000,000.0                        
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First BLA approval - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue       $ 20,000,000.0                          
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               5,000,000.0  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First MAA approval - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               10,000,000.0  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue $ 15,000,000                             15,000,000  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Second commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               25,000,000.0  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Third commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               50,000,000.0  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Fourth commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               75,000,000.0  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Milestones recognized through September 30, 2024                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                               108,000,000.0  
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Milestones that may be recognized in the future                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               165,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                           $ 1,000,000.0      
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | IND clearance from the FDA                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                       $ 4,000,000.0          
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Phase 2 clinical trial initiation                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                   $ 3,000,000.0              
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Phase 3 clinical trial initiation - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue     $ 5,000,000.0                            
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Phase 3 clinical trial initiation - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               5,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first BLA - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               10,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first MAA - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               5,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first BLA - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               10,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First BLA approval - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               20,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First MAA approval - first indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               10,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First BLA approval - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               20,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first MAA - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               5,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First MAA approval - second indication                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               10,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               15,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Second commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               25,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Third commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               50,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Fourth commercial sales milestone                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               75,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Milestones recognized through September 30, 2024                                  
Disaggregation of Revenue [Line Items]                                  
Collaboration revenue                               13,000,000.0  
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Milestones that may be recognized in the future                                  
Disaggregation of Revenue [Line Items]                                  
Milestones that may be recognized in the future                               $ 260,000,000.0